Vallejo C, Jarque I., Fortún J,Pemán J, Muñoz A, and the IFIStrategy Study Group*
A Spanish National Survey on strategies for management of invasive fungal infection and guidelines application in high risk onco-hematological patients
27th Congress of European Hematology Association. Viena. 15-17 jun 2022
Bastos-Oreiro M, Presa M, de las Heras A, Casado MA, Pardo C, Martín-Escudero V, Sureda A
Cost-effectiveness analysis of axicabtagene ciloleucel vs tisagenlecleucel for the management of diffuse large B-cell lymphoma in Spain
26th Congress of European Hematology Association (EHA). Virtual meeting. 9-17 jul 2021
Sierra J, Briones J, Calleja MA, Camacho C, Casado MA, Presa M, Díez JL, Solano C, Moraleda JM, Caballero D
Axicabtagene ciloleucel for the management of patients with diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma: an economic evaluation for Spain
25th European Hematology Association Congress. Virtual. 11-14 jun 2020
Sierra J, Mareque M, Montesinos P, Guinea JM, Font P, Oyagüez I, Brockbank J, Candini D, Llinares J, Soto J, De La Fuente A
Cost-effectiveness of gemtuzumab ozogamicin in combination with standard of care chemotherapy for first-line treatment of patients with CD33-positive acute myeloid leukemia in Spain
25th European Hematology Association Congress. Virtual. 11-14 jun 2020
Sabater E, Rueda A, Salar A, López-Guillermo A, Oyagüez I, Collar JM